PRKCG (Ab-655) Antibody

What is PRKCG and what cellular functions does it regulate?

PRKCG (Protein Kinase C gamma) is a calcium-activated, phospholipid- and diacylglycerol (DAG)-dependent serine/threonine-protein kinase that plays diverse roles in neuronal cells and eye tissues. It functions in multiple neuronal processes, including:

• Regulation of neuronal receptors GRIA4/GLUR4 and GRIN1/NMDAR1

• Modulation of receptors related to sensitivity to opiates, pain, and alcohol

• Mediation of synaptic function and cell survival after ischemia

• Inhibition of gap junction activity after oxidative stress

• Potential involvement in hippocampal long-term potentiation (LTP)

PRKCG binds and phosphorylates GRIA4/GLUR4 glutamate receptors, increasing their plasma membrane expression. In cerebellar neurons, it functions downstream of metabotropic glutamate receptor GRM5/MGLUR5 and phosphorylates GRIN1/NMDAR1 receptor, which plays a key role in synaptic plasticity, synaptogenesis, excitotoxicity, memory acquisition, and learning .

What are the key specifications of the PRKCG (Ab-655) Antibody?

The PRKCG (Ab-655) Antibody is a rabbit polyclonal antibody with the following specifications:

The antibody detects endogenous levels of total PRKCG protein .

What experimental applications is the PRKCG (Ab-655) Antibody validated for?

The PRKCG (Ab-655) Antibody has been validated for the following applications:

• Western Blotting (WB): The antibody has been scientifically validated for Western blot analysis of protein extracts from rat brain cells, where it successfully detects endogenous PRKCG .

• ELISA (Enzyme-Linked Immunosorbent Assay): The antibody is suitable for ELISA applications, providing researchers with a method for quantitative detection of PRKCG in samples .

For Western blot applications, the antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen, ensuring high specificity for the target protein .

What are the optimal storage conditions for maintaining antibody functionality?

For optimal preservation of PRKCG (Ab-655) Antibody functionality, researchers should follow these storage guidelines:

• Store the antibody at -20°C or -80°C upon receipt

• Avoid repeated freeze-thaw cycles, as this can diminish antibody activity and performance

• The antibody is provided in a stabilizing solution containing 50% glycerol, which helps maintain integrity during freeze-thaw cycles when necessary

• The preservative 0.02% sodium azide in the formulation helps prevent microbial contamination during storage

Long-term stability is best maintained by minimizing exposure to room temperature and dividing the antibody into smaller working aliquots before freezing if multiple uses are anticipated.

How can the PRKCG (Ab-655) Antibody be used to study PKC gamma mutations associated with SCA14?

The PRKCG (Ab-655) Antibody can be a valuable tool for studying Spinocerebellar Ataxia Type 14 (SCA14), a neurodegenerative disease caused by germline variants in PRKCG. Researchers can employ this antibody in several advanced applications:

• Protein Expression Analysis: Western blotting can be used to compare expression levels of wild-type versus mutant PRKCG in patient-derived samples, transgenic mouse models (such as the H101Y PKCγ model), or cell culture systems expressing SCA14-associated mutations.

• Autoinhibition Studies: Recent research shows that SCA14-associated PKCγ mutations enhance basal activity by compromising autoinhibition. This antibody can help assess protein levels in experiments examining how mutations in C1 domains protect PKCγ from phorbol ester-induced downregulation .

• Phosphoproteomic Correlation: The antibody can be used in immunoprecipitation experiments prior to mass spectrometry analysis to help identify altered phosphorylation patterns in cerebella expressing SCA14 mutations, as was done in studies of the H101Y mutation .

• Structure-Function Studies: Since most SCA14 variants cluster to the C1B domain or areas that interface with it, this antibody can assist in detecting protein in biochemical studies examining structural consequences of these mutations .

The severity of SCA14 appears to correlate with the degree of disrupted autoinhibition, making the detection of total PRKCG levels critical for understanding disease mechanisms and potential therapeutic strategies .

What controls and validation steps should be used when employing the PRKCG (Ab-655) Antibody?

When utilizing the PRKCG (Ab-655) Antibody in research applications, the following controls and validation steps are recommended:

• Positive Tissue Controls:

  • Rat brain tissue extracts have been validated as an appropriate positive control tissue

  • Cerebellar tissue is particularly relevant due to the high expression of PRKCG in Purkinje cells

• Negative Controls:

  • Include samples from tissues with minimal PRKCG expression

  • Consider using knockdown/knockout samples where PRKCG expression has been reduced/eliminated via genetic approaches

  • Include primary antibody-omitted controls in immunodetection protocols

• Validation in Overexpression Systems:

  • HeLa or HEK293T cells transfected with wild-type or mutant PRKCG can serve as controls, similar to the approach used in studies examining PRKCG-A24E overexpression

• Secondary Antibody Validation:

  • Compatible secondary antibodies include:

    • Goat Anti-Rabbit IgG H&L Antibody (AP)

    • Goat Anti-Rabbit IgG H&L Antibody (Biotin)

    • Goat Anti-Rabbit IgG H&L Antibody (FITC)

    • Goat Anti-Rabbit IgG H&L Antibody (HRP)

• Specificity Testing:

  • If studying SCA14 mutations, compare detection in samples expressing wild-type versus mutant PRKCG

  • Consider using peptide competition assays with the immunizing peptide to confirm specificity

How can researchers optimize Western blot conditions for detecting PRKCG with the Ab-655 antibody?

To obtain optimal results when using PRKCG (Ab-655) Antibody in Western blotting applications, researchers should consider the following protocol optimizations:

• Sample Preparation:

  • For neural tissues: Use cold lysis buffers containing phosphatase inhibitors to preserve phosphorylation states

  • Recommended lysis buffer: RIPA buffer supplemented with protease and phosphatase inhibitor cocktails

  • Brain tissue samples require efficient homogenization followed by clearing centrifugation

• Protein Loading:

  • Load 10-30 μg of total protein per lane for cell lysates

  • For brain tissue lysates, 20-50 μg of total protein typically provides optimal detection

  • Transfer efficiency can be verified using reversible protein stains before blocking

• Blocking Conditions:

  • 5% non-fat dry milk or BSA in TBST (TBS + 0.1% Tween-20)

  • Block for 1 hour at room temperature

• Antibody Dilution and Incubation:

  • Primary antibody: 1:500 to 1:1000 dilution in blocking buffer

  • Incubate overnight at 4°C for optimal signal-to-noise ratio

  • Secondary antibody: HRP-conjugated anti-rabbit IgG at 1:2000 to 1:5000

• Detection:

  • Enhanced chemiluminescence (ECL) systems provide sufficient sensitivity

  • PRKCG appears at approximately 78-80 kDa on reducing SDS-PAGE gels

As demonstrated in the scientific validation data, this antibody successfully detects PRKCG in rat brain cell extracts when following similar protocol parameters .

How can this antibody be used to investigate the role of PRKCG in cerebellar pathophysiology?

The PRKCG (Ab-655) Antibody can be instrumental in investigating cerebellar pathophysiology, particularly in relation to SCA14 and other cerebellar disorders, through several research approaches:

• Transgenic Mouse Model Studies:

  • Western blot analysis of cerebellar extracts from transgenic mice expressing human PKCγ variants (such as H101Y) compared to wild-type

  • Examination of age-dependent changes in PRKCG expression levels in mouse models of cerebellar ataxia

• Phosphoproteomic Analysis:

  • PRKCG detection in immunoprecipitation experiments preceding phosphoproteomic analysis

  • Investigation of how PRKCG mutations affect downstream phosphorylation targets

  • Recent studies have identified that aberrant PKCγ significantly alters proteins controlling synaptic transmission, axon extension, and other neuronal functions

• Long-Term Depression (LTD) Mechanisms:

  • Investigation of PRKCG's relationship with other PKC isoforms, particularly PKCα

  • Analysis of how mutant PRKCG affects PKCα function in Purkinje cells

  • Studies have shown that SCA14 mutant PKCγ (S119P) impairs LTD induction in Purkinje cells and decreases PKCα membrane residence time

• Diacylglycerol Kinase (DGK) Regulation:

  • Examination of PRKCG's role in regulating DGK isozymes, particularly DGKγ and DGKθ

  • Investigation of phosphorylation changes in DGKθ at Ser22 and Ser26, which were significantly increased in H101Y mice

  • This could provide insight into the hypothesis that enhanced basal PRKCG activity drives ataxia by promoting DGK-dependent depletion of diacylglycerol, ultimately impairing PKCα activity and cerebellar LTD

What are the limitations of the PRKCG (Ab-655) Antibody in research applications?

Researchers should be aware of several limitations when working with the PRKCG (Ab-655) Antibody:

• Phosphorylation State Specificity:

  • The antibody was generated against a non-phosphopeptide around the T655 phosphorylation site

  • It detects total PRKCG protein rather than specifically identifying the phosphorylated form

  • For phosphorylation-specific detection, researchers would need a phospho-specific antibody

• Application Constraints:

  • While validated for Western blot and ELISA, its use in other applications like immunohistochemistry, immunofluorescence, or immunoprecipitation may require additional optimization and validation

  • The search results do not show validation for flow cytometry or other advanced applications

• Species Limitation:

  • Confirmed reactivity is limited to human, mouse, and rat samples

  • Cross-reactivity with other species would need to be empirically determined

• Isoform Discrimination:

  • The antibody may not distinguish between PKCγ and other PKC isoforms if there is significant sequence homology around the target epitope

  • Additional controls may be needed when studying tissues expressing multiple PKC isoforms

• Mutant Detection Considerations:

  • When studying SCA14 mutations, researchers should be aware that some mutations might alter the epitope recognized by this antibody

  • Validation experiments comparing detection of wild-type versus mutant PRKCG should be performed when studying specific mutations

How does research on PRKCG contribute to understanding neurodegenerative disorders?

Research on PRKCG using tools like the Ab-655 antibody contributes significantly to understanding neurodegenerative disorders, particularly SCA14, in the following ways:

• Mechanism of Pathogenesis:

  • Recent research has revealed that ataxia-associated PKCγ mutations enhance basal activity by compromising autoinhibition

  • The degree of disrupted autoinhibition correlates with disease severity, with higher basal activity associated with earlier disease onset

  • While impaired autoinhibition typically leads to PKC degradation, C1 domain mutations in SCA14 protect PKCγ from phorbol ester-induced downregulation

• Cerebellar Phosphoproteome Insights:

  • Phosphoproteomic analysis of cerebella from mice expressing mutant PKCγ (H101Y) reveals how enhanced basal signaling rewires the brain phosphoproteome

  • This provides a broader understanding of how kinase dysfunction impacts cellular signaling networks in neurodegenerative conditions

• Structure-Function Relationships:

  • Molecular modeling indicates that most SCA14 variants not located in C1 domains are at interfaces with the C1B domain

  • Bioinformatics analysis reveals that variants in the C1B domain are under-represented in cancer

  • This suggests that clustering of SCA14 variants to the C1B domain provides a unique mechanism to enhance PKCγ basal activity while protecting the enzyme from downregulation

• Potential Therapeutic Targets:

  • Understanding how PRKCG mutations affect DGK activity and diacylglycerol levels provides potential therapeutic targets

  • Research suggests that the LTD deficits in SCA14 may result from PKCγ-induced dysregulation of PKCα function via DGK activation

  • This knowledge might inform development of isoform-specific PKC modulators or DGK inhibitors for treating cerebellar ataxias

What novel SCA14 mutations have been identified in recent research and how can they be studied with this antibody?

Recent research has identified several SCA14 mutations, including a previously undescribed variant, D115Y, which can be studied using the PRKCG (Ab-655) Antibody:

• D115Y Variant:

  • A newly described variant associated with later disease onset

  • Molecular modeling indicates D115Y is at an interface with the kinase domain

  • The mutation to tyrosine could break interdomain interactions to favor the 'open' conformation due to the bulkier side chain and loss of negative charge

  • Phorbol ester-dependent translocation of D115Y PKCγ was considerably greater than wild-type PKCγ, consistent with a more exposed C1B domain

  • D115Y causes only a modest enhancement of basal signaling, resulting in less severe pathology

• H101Y Mutation:

  • This mutation has been extensively studied using transgenic mouse models

  • Phosphoproteomic analysis of cerebella from mice expressing this human PKCγ transgene shows significant alterations in the phosphoproteome

  • The antibody can be used to confirm expression levels of the mutant protein in these models

• Other Relevant Mutations:

  • S119P mutation has been shown to interfere with PKCα function in Purkinje cells

  • A24E and A24T mutations have been investigated in overexpression studies in HeLa and HEK293T cells

The PRKCG (Ab-655) Antibody can be used to:

It's worth noting that the proximity of certain mutations to the antibody's target epitope (around T655) should be considered when interpreting results, as nearby mutations might potentially affect antibody binding.

What sample preparation methods optimize detection of PRKCG in neural tissues?

For optimal detection of PRKCG in neural tissues using the Ab-655 antibody, researchers should consider the following sample preparation methods:

• Tissue Collection and Preservation:

  • Fresh tissue should be immediately snap-frozen in liquid nitrogen

  • For fixed tissues, brief fixation (4-8 hours) in 4% paraformaldehyde is recommended to preserve protein structure while allowing for antibody accessibility

  • Cryoprotection in sucrose gradients (15-30%) before freezing can help maintain tissue integrity

• Protein Extraction:

  • For cerebellar tissue, where PRKCG is highly expressed in Purkinje cells:

    • Homogenize in ice-cold RIPA buffer (50 mM Tris-HCl pH 7.4, 150 mM NaCl, 1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS)

    • Supplement with protease inhibitor cocktail and phosphatase inhibitors (sodium fluoride, sodium orthovanadate)

    • Include 1 mM DTT to maintain protein stability

  • Use a Dounce homogenizer with 10-15 strokes for efficient cell disruption while preserving protein integrity

• Clearing and Fractionation:

  • Centrifuge homogenates at 14,000 × g for 15 minutes at 4°C to remove debris

  • For membrane vs. cytosolic fractionation (useful for studying PKC translocation):

    • Centrifuge homogenates at 100,000 × g for 1 hour

    • The supernatant contains cytosolic proteins, while the pellet (resuspended in buffer containing 1% Triton X-100) contains membrane proteins

• Protein Quantification and Sample Preparation:

  • Determine protein concentration using BCA or Bradford assay

  • Prepare samples in Laemmli buffer with 5% β-mercaptoethanol

  • Heat samples at 95°C for 5 minutes to denature proteins

  • For cerebellar samples, load 20-40 μg of total protein per lane for optimal detection

• Special Considerations for Phosphorylation Studies:

  • When studying phosphorylation events:

    • Add phosphatase inhibitors (10 mM sodium fluoride, 1 mM sodium orthovanadate, 1 mM sodium molybdate, 4 mM sodium tartrate)

    • Process samples rapidly at 4°C to minimize dephosphorylation

    • Consider using Phos-tag™ acrylamide gels for enhanced separation of phosphorylated species

How can the PRKCG (Ab-655) Antibody be integrated with other research techniques for comprehensive studies?

The PRKCG (Ab-655) Antibody can be integrated with multiple research techniques to create comprehensive experimental approaches:

• Combination with Phospho-Specific Antibodies:

  • Use in parallel with phospho-specific PRKCG antibodies to distinguish between total protein levels and activation state

  • Sequential probing of the same membrane can provide direct comparison of total vs. phosphorylated protein on the same samples

• Immunofluorescence Microscopy Integration:

  • Although not specifically validated for immunofluorescence, optimization for this application could allow:

    • Visualization of PRKCG localization in neuronal cells

    • Co-localization studies with other proteins like GRIA4/GLUR4 and GRIN1/NMDAR1 receptors

    • Examination of translocation dynamics in response to calcium and DAG signaling

• Integration with FRET-Based Activity Reporters:

  • When paired with FRET-based PKC activity reporters (as used in SCA14 research):

    • The antibody can confirm protein expression levels while the FRET reporter measures activity

    • This combination can help correlate protein levels with functional activity, particularly important when studying autoinhibition defects

• Complementing Phosphoproteomic Studies:

  • In phosphoproteomic workflows:

    • Confirm PRKCG expression levels before mass spectrometry analysis

    • Validate changes in specific phosphorylation sites identified in phosphoproteomic screens

    • Paired with bioinformatics analysis to identify affected pathways

• Integration with Electrophysiological Techniques:

  • In studies of long-term depression (LTD) in Purkinje cells:

    • Confirm PRKCG expression in parallel with patch-clamp recordings

    • Correlate protein levels with functional deficits in synaptic plasticity

    • This is particularly relevant given findings that SCA14 mutant PKCγ impairs LTD induction

• Cell-Based Functional Assays:

  • Detection of PRKCG expression levels in cells undergoing:

    • Membrane translocation assays

    • Protein degradation studies

    • Phorbol ester-induced downregulation experiments

  • This can help correlate protein levels with functional outcomes in cellular models of SCA14

What emerging research questions about PRKCG could be addressed using this antibody?

The PRKCG (Ab-655) Antibody could be instrumental in addressing several emerging research questions in the field:

• Differential Degradation Pathways:

  • Recent findings suggest separate degradation pathways exist for basal PKC turnover versus activated PKC degradation

  • The antibody could help investigate how SCA14 mutations uncouple agonist-dependent turnover from basal turnover

  • Studies could examine the role of the E3 ligase RINCK and proteasome-dependent versus proteasome-independent degradation pathways

• PKCγ-PKCα Functional Interactions:

  • Evidence suggests aberrant PKCγ in SCA14 may reduce PKCα function

  • Research could investigate:

    • How mutant PKCγ affects PKCα membrane residence time

    • Whether competition for binding partners or altered scaffolding is involved

    • If PKCγ mutations create a dominant-negative effect on PKCα activity

• Diacylglycerol Kinase Regulation:

  • Phosphoproteomic studies identified increased phosphorylation of DGKθ at Ser22 and Ser26 in H101Y PKCγ mice

  • Future research could investigate:

    • How these phosphorylation events affect DGK activity

    • Whether altered DG levels are a key mechanism in SCA14 pathogenesis

    • If DGK inhibitors might represent therapeutic targets for SCA14

• Age-Dependent Changes in PRKCG Function:

  • SCA14 typically manifests in adulthood despite expression of mutant PKCγ throughout development

  • Studies could examine:

    • Age-dependent changes in PKCγ expression, localization, and interactome

    • Compensatory mechanisms that might delay disease onset

    • Whether age-related changes in calcium homeostasis exacerbate PKCγ dysfunction

• Novel Therapeutic Approaches Based on Autoinhibition Mechanisms:

  • Given that impaired autoinhibition drives SCA14 pathogenesis:

    • Development of compounds that restore autoinhibitory constraints

    • Investigation of whether enhancing specific protein-protein interactions could compensate for disrupted autoinhibition

    • Screening for small molecules that selectively modulate aberrantly active PKCγ without affecting wild-type function

How might the PRKCG (Ab-655) Antibody contribute to developing potential therapeutics for SCA14?

The PRKCG (Ab-655) Antibody could make significant contributions to therapeutic development for SCA14 through several research applications:

• Target Validation Studies:

  • Western blot analysis to confirm target engagement in drug screening assays

  • Verification of PRKCG levels in response to potential therapeutic compounds

  • Assessment of whether treatments affect total protein levels or just activity

• Biomarker Development:

  • Investigation of whether peripheral PRKCG detection could serve as a biomarker for disease progression

  • Correlation of cerebellar PRKCG levels with disease severity in animal models

  • Assessment of treatment response in preclinical studies

• Therapeutic Screening Platforms:

  • Validation of high-throughput screening systems targeting:

    • Compounds that restore autoinhibitory constraints

    • Modulators of DGK activity

    • Regulators of PKCα function that might compensate for PKCγ dysfunction

  • Confirmation of hit compound effects on PRKCG levels and stability

• Gene Therapy Approaches:

  • In research exploring RNA interference or antisense oligonucleotide approaches:

    • Verification of selective knockdown of mutant PRKCG while preserving wild-type expression

    • Assessment of total PRKCG levels following allele-specific targeting

    • Correlation of protein levels with functional outcomes

• Mechanism-Based Therapeutic Development:

  • Based on the finding that disrupted autoinhibition drives pathology:

    • Evaluation of compounds that preferentially bind to and stabilize the autoinhibited conformation

    • Testing of agents that modulate C1B domain interactions

    • Screening for drugs that selectively reduce basal activity without affecting agonist-stimulated responses

• Long-Term Depression (LTD) Restoration Strategies:

  • Investigation of approaches to restore cerebellar LTD in the presence of mutant PRKCG:

    • Direct targeting of PKCα function

    • Modulation of DG levels through DGK inhibition

    • Evaluation of compounds that affect downstream PKC targets

Through these applications, the PRKCG (Ab-655) Antibody can provide critical insights for therapeutic development while serving as an essential tool for validating treatment effects at the protein level.